Payment overview · 2025
General Payments
$1,990.77
90 reported records · 31 companies
Healthcare provider profile · identity verified
F. Geoffery Conner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VIDALIA, GA · NPI 1902942220
Verified facts
What the public records show
CMS Open Payments records show F. Geoffery Conner, MD received $1,990.77 in general payments during 2025 across 90 reported records.
AstraZeneca Pharmaceuticals LP accounted for 11.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Fasenra, Linzess, Mounjaro, Nexletol, Qulipta, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 717 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Viibryd by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FASENRA as an associated drug or biological on 40035 records involving 10417 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fasenra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 419 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 354 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Entresto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Xolair by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lantus by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $221.59 | 11.1% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $205.46 | 10.3% | 13 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $174.25 | 8.8% | 7 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $166.25 | 8.3% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $158.02 | 7.9% | 7 | 2025 |
| KVK-Tech, Inc. | Unresolved — no canonical attribution shown | $126.57 | 6.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $121.57 | 6.1% | 6 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $107.68 | 5.4% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $82.70 | 4.2% | 4 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $67.81 | 3.4% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $55.99 | 2.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $47.67 | 2.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.62 | 2.2% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $38.60 | 1.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.46 | 1.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.00 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.90 | 1.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.17 | 1.6% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.13 | 1.6% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.80 | 1.0% | 1 | 2025 |
| Hikma Pharmaceuticals USA | Unresolved — no canonical attribution shown | $19.75 | 1.0% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $19.06 | 1.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.01 | 0.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.84 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.19 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.48 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.90 | 0.8% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.90 | 0.8% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.60 | 0.7% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $14.34 | 0.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.46 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,844.77 | 87 |
| Education | $146.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $338.95 | 10 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $183.31 | 9 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $158.02 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $132.57 | 8 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $121.57 | 6 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $91.11 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $86.22 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $82.70 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $73.79 | 2 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $67.81 | 3 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $47.67 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $38.60 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.90 | 2 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | Octapharma USA, Inc., PFIZER INC. | $31.82 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.17 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.13 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| Ryaltris Normalized: ryaltris |
Drug | Hikma Pharmaceuticals USA | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.90 | 2 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 232 | exact normalized | Medicare Part D |
| FASENRA fasenra |
2025 | Fasenra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 131 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 354 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 189 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
131 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
717 | 118 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
37 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
232 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FASENRA open payments reported associated product |
CMS Open Payments — General Payments 40035 supporting records · 10417 recipient NPIs · example record 1206131346 |
Fasenra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
214 | 53 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
297 | 297 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
189 | 155 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
419 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
354 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
285 | 54 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 966 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 897 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 861 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 828 | 148 |
| Synthroid | Levothyroxine Sodium | 717 | 118 |
| Gabapentin | Gabapentin | 688 | 135 |
| Furosemide | Furosemide | 641 | 142 |
| Losartan Potassium | Losartan Potassium | 628 | 127 |
| Fluticasone Propionate | Fluticasone Propionate | 601 | 156 |
| Omeprazole | Omeprazole | 553 | 104 |
| Potassium Chloride | Potassium Chloride | 550 | 103 |
| Famotidine | Famotidine | 540 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 485 | 96 |
| Simvastatin | Simvastatin | 480 | 93 |
| Escitalopram Oxalate | Escitalopram Oxalate | 468 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 466 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 461 | 100 |
| Valsartan | Valsartan | 457 | 88 |
| Metformin Hcl | Metformin Hcl | 434 | 74 |
| Jardiance | Empagliflozin | 419 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 415 | 78 |
| Donepezil Hcl | Donepezil Hcl | 396 | 58 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 374 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 373 | 107 |
| Mounjaro | Tirzepatide | 354 | 52 |
| Carvedilol | Carvedilol | 347 | 69 |
| Ezetimibe | Ezetimibe | 323 | 54 |
| Lorazepam | Lorazepam | 318 | 66 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 297 | 297 |
| Duloxetine Hcl | Duloxetine Hcl | 297 | 49 |
| Eliquis | Apixaban | 285 | 54 |
| Allopurinol | Allopurinol | 272 | 54 |
| Pioglitazone Hcl | Pioglitazone Hcl | 268 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 60 |
| Lisinopril | Lisinopril | 266 | 64 |
| Rabeprazole Sodium | Rabeprazole Sodium | 238 | 43 |
| Farxiga | Dapagliflozin Propanediol | 232 | 35 |
| Temazepam | Temazepam | 229 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 227 | 35 |
| Symbicort | Budesonide/Formoterol Fumarate | 214 | 53 |
| Ozempic | Semaglutide | 208 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 204 | 59 |
| Meloxicam | Meloxicam | 196 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 193 | 35 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 189 | 155 |
| Alprazolam | Alprazolam | 182 | 32 |
| Tramadol Hcl | Tramadol Hcl | 176 | 42 |
| Sertraline Hcl | Sertraline Hcl | 173 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 35 |
| Trazodone Hcl | Trazodone Hcl | 172 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 170 | 24 |
| Azelastine Hcl | Azelastine Hcl | 169 | 58 |
| Buspirone Hcl | Buspirone Hcl | 168 | 33 |
| Pregabalin | Pregabalin | 165 | 28 |
| Gemfibrozil | Gemfibrozil | 157 | 24 |
| Memantine Hcl Er | Memantine Hcl | 151 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 147 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 144 | 29 |
| Finasteride | Finasteride | 137 | 27 |
| Linzess | Linaclotide | 131 | 35 |
| Nebivolol Hcl | Nebivolol Hcl | 126 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 32 |
| Benazepril Hcl | Benazepril Hcl | 118 | 24 |
| Clonazepam | Clonazepam | 117 | 20 |
| Colchicine | Colchicine | 112 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 111 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 107 | 17 |
| Spiriva Respimat | Tiotropium Bromide | 106 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 13 |
| Primidone | Primidone | 99 | 19 |
| Spironolactone | Spironolactone | 97 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 95 | 16 |
| Cefuroxime | Cefuroxime Axetil | 94 | 75 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 94 | 24 |
| Xarelto | Rivaroxaban | 92 | 15 |
| Ondansetron Odt | Ondansetron | 88 | 48 |
| Prednisone | Prednisone | 87 | 35 |
| Tresiba Flextouch U-200 | Insulin Degludec | 87 | 18 |
| Glipizide | Glipizide | 84 | 19 |
| Celecoxib | Celecoxib | 83 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 82 | 17 |
| Memantine Hcl | Memantine Hcl | 81 | 13 |
| Lansoprazole | Lansoprazole | 80 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 80 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 53 |
| Chlorthalidone | Chlorthalidone | 78 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 77 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 32 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 75 | 44 |
| Entresto | Sacubitril/Valsartan | 74 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 74 | 14 |
| Sucralfate | Sucralfate | 74 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 74 | 13 |
| Atenolol | Atenolol | 73 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 30 |
| Alendronate Sodium | Alendronate Sodium | 70 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 60 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 57 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 12 |
| Labetalol Hcl | Labetalol Hcl | 54 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 53 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | suppressed |
| Fluconazole | Fluconazole | 53 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 51 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 11 |
| Meclizine Hcl | Meclizine Hcl | 51 | 15 |
| Xolair | Omalizumab | 51 | suppressed |
| Dulera | Mometasone/Formoterol | 49 | 13 |
| Epinephrine | Epinephrine | 49 | 34 |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 17 |
| Eszopiclone | Eszopiclone | 47 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | 18 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 42 | suppressed |
| Estradiol | Estradiol | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 39 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 24 |
| Vascepa | Icosapent Ethyl | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 39 | suppressed |
| Roflumilast | Roflumilast | 38 | suppressed |
| Prolia | Denosumab | 37 | 23 |
| Diazepam | Diazepam | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Nexletol | Bempedoic Acid | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 27 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | 11 |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 18 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 18 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 16 | suppressed |
| Cimetidine | Cimetidine | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Dupixent Pen | Dupilumab | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Alprazolam Xr | Alprazolam | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Cymbalta | Duloxetine Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Viibryd | Vilazodone Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fasenra | Benralizumab | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,990.77 · 90 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AJOVY, CONTRAVE, CUTAQUIG, CUVITRU, DUPIXENT, Dexcom G6 Transmitter, FARXIGA, FASENRA, Fluad, Flucelvax, GVOKE HYPOPEN, Kerendia, Korlym, LINZESS, MOUNJARO, NEFFY, NEXLETOL, ORLADEYO, PANZYGA, Prolastin-C Liquid, QULIPTA, Quviviq, Rhapsido, Ryaltris, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, UNITHROID, VERQUVO, VIBERZI, VOQUEZNA, Xembify, ZEPBOUND, ZORYVE | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error